Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

Here's the Average Social Security Retired-Worker Benefit by Age (From 62 Through 99-Plus)

View original at nasdaq.com
Here's the Average Social Security Retired-Worker Benefit by Age (From 62 Through 99-Plus) Key Points Nearly a quarter-century of Gallup surveys show that Social Security income is relied upon by up to 90% of retirees to make ends meet…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 26% of mothers were stay-at-home parents compared to just 7% of fathers

    60% confidence
  • 80% to 90% of retirees rely on their Social Security payout to cover some portion of their expenses

    60% confidence
  • Up to 90% of retirees rely on Social Security income to make ends meet

    60% confidence
  • Claiming at age 62 can permanently reduce a worker's monthly payout by 25% to 30%, depending on their birth year

    60% confidence
  • Spending more time out of the labor force has negatively impacted the earning potential for women, resulting in the observed drop-off in average retired-worker payouts from age 85 onward

    60% confidence
  • For every year a worker waits to initially collect their benefit, from age 62 until age 70, their payout can grow by up to 8%

    60% confidence
  • One easy trick could pay you as much as $23,760 more each year in Social Security benefits

    60% confidence
  • Waiting until age 70 to initially collect benefits can increase their benefit by 24% to 32% above what they'd receive at full retirement age

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Here's the Average Social Security Retired-Worker Benefit by Age (From 62 Through 99-Plus) — Source | Via News | ViaNews Market